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Abstract
Background: Medicine shortages are a complex global challenge affecting all countries. This includes South Africa
where ongoing medicine shortages are a concern among public sector hospitals as South Africa strives for universal
access to healthcare. The objectives of this research were to highlight challenges in the current pharmaceutical
procurement process for public sector hospitals. Subsequently, suggest potential ways forward based on the
findings as the authorities in South Africa seek to improve the procurement process.
Method: Qualitative in-depth interviews were conducted with 10 pharmacy managers in public sector hospitals in
the Gauteng Province, South Africa. A thematic content analysis was performed, with transcripts coded by two of
the authors. Coding was discussed until consensus was reached. Categories were developed and grouped into
themes.
Results: The ‘Procurement process’ emerged from the data as the overarching theme, rooted in three main
themes: (i) The buy-out process that was used to procure medicines from suppliers other than the contracted ones;
(ii) Suppliers not performing thereby contributing to medicine shortages in the hospitals; and (iii) Challenges such
as the inaccuracy of the electronic inventory management system used in the hospitals.
Conclusions: Effective management of contracts of suppliers by the Provincial Department of Health is crucial to
ensure accessibility and availability of essential medicines to all citizens of South Africa. Ongoing monitoring and
support for the future use of computerised inventory management systems is important to reduce medicine
shortages, and this is being followed up.
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Background
Over the years, the shortage of medicines has been a
challenge to the effective delivery of quality healthcare
services worldwide including South Africa [1–10], with
shortages of even essential medicines becoming a global
problem irrespective of the economic status of countries
[11–13]. More than half of the world’s population do
not have access to essential services [14], exacerbated by
medicine shortages. The origins of medicine shortages
are complicated, can differ among regions and countries,
and consequently potentially require different strategies
to address them [5, 6, 15]. In the United States (US), the
total number of new and ongoing shortages exceeded
450 in 2012 [12]. Overall in the US, as many as 99% of
pharmacists in a study published in 2014 reported ex-
periencing at least one shortage during the previous 12
months, 64% reported that their facility had completely
run out of at least one injectable oncology drug during
the past 12 months and 25% reported that one or more
safety events had occurred at their facility as a result of
shortages of medicines [16]. In Europe, a recent survey
among hospital pharmacists showed there had been a
significant increase in medicine shortages across Europe
with 91.8% hospital pharmacists in 2018 experiencing
shortages compared to 86.2% in 2014, with 35% experi-
encing them on a daily basis and 38% on a weekly basis
[17], which is a concern. There are also considerable
shortages in other continents and countries including
other low and middle income countries (LMICs) across
South America and wider [5, 6, 8, 9].
Some of the contributing factors to the shortage of
medicines include manufacturing and quality problems,
production delays, lack of manufacturing capacity, short-
age of raw materials, political instability, and profitability
issues [5, 6, 8, 9, 18]. Other factors include long lead
times, delays in awarding tenders, absence of national
contracts on the regional code lists of medicines, the
failure of suppliers to meet demand, and the failure to
pay suppliers [2, 19, 20].
The continuous and adequate supply of medicines is a
key element in managing diseases especially chronic dis-
eases [21], with the availability of essential medicines
dependent on efficient supply chain systems among
other factors [22]. Good systems are the ecosystem of
organizations, with people, technologies, and activities
brought together to ensure good delivery of medicines
from manufacture right through to the end user, the pa-
tient, at affordable and acceptable prices [2, 6]. The key
being to identify and rectify problems as early as pos-
sible. Regulatory issues contribute to the shortage of
medicines especially if companies are unable to meet
Good Manufacturing Practice and have their facilities
closed down following an inspection of their facilities
[23]. Early mandatory notification by manufacturers of
any discontinuation or disruption in the manufacturing
of a drug that could lead to a shortage is necessary in
the management of medicine shortages are welcomed,
with such systems in place in a number of European and
other countries [5, 6, 24]. The Food and Drug Adminis-
tration in the US adopted this particular strategy, which
has resulted in quicker and more effective responses to
medicine shortages [24].
Pharmacists, as the custodians of medicines, do play a
critical role in the management of pharmaceuticals to
help ensure the availability of medicines to patients in
the public sector [25]. The pharmacy department espe-
cially in hospitals can also better manage the shortage of
medicines by ensuring that in its organization, there are
well defined management strategies. Infrastructures such
as drug shortage teams, resource allocation committees,
and processes for approving alternative therapies are im-
portant considerations in hospitals [26–28]. It is also im-
portant that healthcare institutions themselves conduct
medicine shortage impact analysis in their institutions in
order to understand the seriousness of current shortages
as well as resources that are potentially available to con-
tain the situation where possible [24]. Potential activities
can include seeking ways to address the issue of, penal-
ties not imposed on suppliers that failed to deliver
within lead times, as well as addressing irregular order-
ing patterns by facilities from the depots [29]. This is an
issue especially among sub-Saharan African countries in-
cluding South Africa [10, 15, 22, 23]. The South African
Healthcare system comprises both the public and private
sectors. The public sector is run and managed by the
government, rendering its services through public hospi-
tals categorised by their levels of care as central, tertiary,
district, and regional as well as clinics. This sector pro-
vides healthcare services to 82.5–84% of the population
while only 17.5% of the population is serviced by the pri-
vate sector [22, 30]. Healthcare services in the public
sector are financed through general tax revenues while
healthcare services in the private sector are largely fi-
nanced by medical aid schemes with a small fraction
financed through out of pocket payments [30]. The
cost of medical schemes has kept the majority of the
population from accessing the services in the private
sector [31]; however, there is controversy regarding
the extent of payments [32].
The selection of medicines in the public health sector in
South Africa is performed by the National Essential Medi-
cines List Committee (NEMLC) appointed by the Minister
of Health [33]. Medicines selection is essentially based on
evidence of efficacy, safety, quality and cost. However,
considering limited financial resources, decision-making
in terms of selection and procurement is informed by the
anticipated disease burden, and subsequent budget impact
analysis. With the future introduction of National Health
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Insurance, pharmacoeconomics evaluations and health
technology assessment will be paramount to medicines
selection [34].
The procurement of medicines and pharmaceutical
supplies is undertaken through an open centralized ten-
der system. The National Department of Health enters
into contracts with the pharmaceutical suppliers on be-
half of the provinces [33]. After the tenders have been
awarded by the NDoH to the suppliers, the provincial
depots perform the quantification and procurement of
pharmaceuticals on behalf of the facilities in their Prov-
ince. The depots are also responsible for warehousing
and distribution of medicines to the facilities [29]. Al-
though most medicines are delivered via this route,
provinces are increasingly relying on direct delivery of
medicines from contracted suppliers to health facilities,
which shortens the supply chain and removes risks and
costs associated with warehousing [35]. Buy-outs can
however occur and this process is used by hospitals to
purchase medicines appearing on the EML but not on
tender. The buy-out process is also used when the
contracted supplier does not perform as agreed [29], and
is not a normal or standard method to purchase phar-
maceuticals. Buy-outs typically occur as a result of late
advertising and award of tenders resulting in consider-
able time and effort spent on this process [29]. Suppliers
who are contracted by the NDoH through a tendering
process are obligated to observe lead times, maintain
good quality of products and supply complete orders. It
is the duty of the provincial DoH to pay the supplier
accounts within a 30 day period from the day of receipt
of valid invoice as stipulated by the Public Finance Man-
agement Act (PFMA) no. 1 of 1999 [36].
The ongoing medicine shortages in public sector hos-
pitals, especially in South Africa, highlight the need to
explore this further [37, 38]. We are aware that there
have been recent programs to help reduce potential
medicine shortages in the public sector in South Africa
[22] building on concerns in some provinces [25]. As a
result, there is a need to gain current understanding of
the experiences of pharmacy managers and drug con-
trollers regarding medicine shortages in South Africa
and potential ways to address this. Drug controllers, a
post unique to the Gauteng province, and assistant man-
agers occupy specialized posts in central and tertiary
hospitals. Their role is to ensure effective and efficient
medicines supply management services through formu-
lary management in their institutions and provide expert
advice and communication to management teams on
matters relating to procurement, logistics management
and use of medicines. They achieve this by making sure
that there is no-over expenditure and that institutions
adhere to Standard Treatment Guidelines (STGs) and
EML [39]. Consequently, the purpose of this study was
to highlight challenges in the pharmaceutical procure-
ment process, reported to have contributed to medicine
shortages in public hospitals in South Africa, to provide
future direction.
Methods
Study design and population
This was a qualitative descriptive study with data col-
lected through in-depth interviews. The target popula-
tion included 32 people including 27 pharmacists who
were pharmacy managers from the four levels of care
(district, regional, tertiary and central) and 5 drug con-
trollers/ assistant managers in the Gauteng Province.
Gauteng province was selected for this initial study due
to ease of access to key personnel in all four levels of
care in public sector hospitals. Participants were then
purposefully selected based on the number of years of
experience in their positions. Request for permission to
conduct the study in the public hospitals was sought
from the Department of Health. After the Gauteng Eth-
ics Committee granted permission for the study to be
conducted, invitations were sent to the 27 hospitals in
the Province 9 hospitals responded and agreed to par-
ticipate in the study. Eight pharmacists were interviewed
from 8 hospitals (one from each) and two pharmacists
were interviewed in one hospital. None of the drug con-
trollers were interviewed in the study. Three of the
hospitals that had drug controllers did not respond to
the invitation and two other drug controllers were not
available to be interviewed at the time the study was
conducted. Data saturation was reached regardless of the
small sample size.
Interview guide and interviews
An interview guide was developed specifically for this
study in line with the study objectives (Supplementary
file 1). The guide involved open ended questions that
allowed probing about (i) the experiences of the phar-
macy managers on the shortage of medicines in their
hospitals; (ii) the impact of medicine shortages for phar-
macy staff and patients; (iii) strategies used to manage
medicines; and (iv) any changes to normal practices to
address medicine shortages. Data were collected through
in depth interviews aimed at gathering information on
the medicines shortage phenomenon and facilitating
fruitful discussions. All interviews were conducted by
the first author in English, the language of communica-
tion in the workplace, between September and Decem-
ber 2017. Arrangements were made via the telephone
for a suitable date for the interview at the participants’
workplace. Interviews took place in a private room with
limited disturbance and were recorded using a digital
voice recorder. Participants provided written informed
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consent for participation in the study and recording of
the interviews.
Analysis
The recorded interviews were transferred from the
digital voice recorder to a computer and stored as Win-
dows Media Audio files. Each interview was transcribed
verbatim and saved as a Microsoft Word® document.
The transcripts were then imported into NVivo 12® a
qualitative data analysis software programme. Tran-
scripts were then coded by the first author and re-coded
by the second author. Continuous discussions took place
between the two authors until a consensus was reached
regarding the coding framework. A thematic analysis ap-
proach was used based on the hermeneutic theory where
data were coded into ranks after a process of classifying
codes and re-classifying sub-codes to ensure that exclu-
sionary themes emerged [40, 41].
Verbatim quotations from participants, presented in
italics text and enclosed in quotation marks, are used in
the results section to illustrate the findings. Quotations
were edited for punctuation to enhance readability and
phrases or words removed from any quotation are re-
placed by three dots where pertinent. Pharmacists’ desig-
nations follow the quotations and are presented in
square brackets.
Ethics
Ethical clearance for the study was obtained from the
Sefako Makgatho University Research Ethics Committee
prior to the commencement of the study (SMUREC/H/
44/2016: PG). Permission to conduct the study was
granted by the National Department of Health (NDoH),
the Gauteng Health Research and Ethics Committee and
the Chief Executive Officers of the participating hospi-
tals. Participants provided written informed consent.
Results
Sample characteristics
Ten pharmacy managers were interviewed, five from
regional hospitals, one from a district hospital, two
from tertiary hospitals and two from a central hos-
pital. This sample was representative of the four
levels of healthcare delivery by public sector hospitals
in the Gauteng Province as well as generally among
the public healthcare system in South Africa. Out of
the ten participants, eight were females and two were
males with age range of 36–61 years, and the average
number of years of experience as pharmacy managers
of 5 years.
Overarching theme: procurement process
An overarching theme ‘Procurement process’ emerged
from the data and is rooted in three main themes (i)
Buy-outs; (ii) Supplier performance; (and (iii) Integrated
computerised inventory management systems (RxSolu-
tion). The main themes are summarised in Fig. 1 and
discussed in more detail below.
Theme 1: buy-out process
Several participants raised concerns about the buy-out
process in their hospitals. According to the participants,
the buy-out process is currently very lengthy. In some
instances, it did not ensure medicines availability at the
time of need due to its complex nature. In fact, some
participants felt that the buy-out process actually con-
tributed to the problem of unavailability of medicines in
their hospitals.
Overall, it was evident from the interviewees that the
buy-out process puts considerable strain on hospital phar-
macists, taking-up time that could have been invested in
other important activities in the pharmacy including en-
suring the rational use of medicines within the hospital.
Essential medicines that were not on tender contrib-
uted to a number of buy-outs that hospitals had to deal
with. One of the participants suggested that the Central
Medicines Depot should take over the buy-out of medi-
cines listed on the EML on behalf of the hospitals to
ease the burden of this process. The participants’ frustra-
tion is illustrated in the following narratives:
“I don’t understand why the Depot is not doing buy-
outs for vital and essential medicine items on the
EML on behalf of the institutions, because the buy-
out process is too much paper work. This process can
easily take at least 4 weeks from the time the
application goes in, to the time stock is received.
Even though I am frustrated and irritated by this, I still
need to do what needs to be done for patients to get
their medication.” (Regional hospital pharmacist 2).
“Buy-outs are not the way out as such, because their
turnaround time is too long. You have to wait for
companies to give you quotations, you sign the
documents and the CEO signs as well and you then
send them to Medical Supplies Depot. You then wait
for a committee that sits at the Depot that decides
whether to approve your application or not, and the
process takes time, six weeks at most. During that
long period of waiting, the hospital would not
have anything and patient care is compromised.”
(Regional hospital pharmacist 5).
Theme 2: supplier performance
Several participants raised several concerns with the
suppliers that they believed contributed to the
medicine shortages. Participants reported that they
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waited for periods longer than 21 days before orders
were received from the suppliers. In some instances,
suppliers did not deliver full quantities of orders.
Some of the participants reported to have received
incorrect information from the suppliers about stock
availability and this also resulted in medicine
shortages in their hospitals. Participants pointed out
that tenders were sometimes given to companies
that did not have the capacity to deliver, which has
important implications for patient care within their
hospitals.
“With the companies the lead time is 21 days, but
you find that there are orders that would be
outstanding for about three months because that
particular company was awarded the contract and
now it does not have stock. The company will claim
that it has stock but when you place orders you find
that they don’t have stock. So it is a serious
problem.” (Regional hospital pharmacist 3).
“And the other thing was that the contracted com-
panies were not able to supply the quantities they
were contracted for. They could not meet the de-
mand.” (Regional hospital pharmacist 1).
Some participants alluded to the fact that suppliers
were unable to deliver on orders placed because of the
shortage of active pharmaceutical ingredients (APIs). As
a result, stock-outs were experienced in their institu-
tions. However, these shortages of APIs were not a
South African phenomenon only.
“The fundamental problem we had a year ago was
the shortage of the APIs apparently worldwide, so it
wasn’t just a problem for South Africa.” (District
hospital pharmacist 1)
Some participants stated non-payment of suppliers as
a contributing factor to medicine shortages in their hos-
pitals. They explained that suppliers who were not paid
Fig. 1 Themes on the procurement process derived from data
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on time did not deliver the stock that was ordered to the
hospitals. As a result, the availability of requested medi-
cines was affected. It was evident from the participants
that the suppliers did not typically communicate with
the hospitals in advance on issues that have the potential
of causing medicine shortages.
“The suppliers were not being paid; and they stopped
supplying because they were owed money. In fact, we
are still trying to recover from that, even now. That has
been the problem.” (District hospital pharmacist 1)
Raising the same view, the regional pharmacy manager
also highlighted the fact that they did not know what the
problem was until they made a follow-up with the sup-
pliers about outstanding orders.
“Sometimes you would call the company to make a
follow-up on the order and you would be told that
your account has been put on hold because of issues of
non-payment, and that does contribute to medicine
shortages.” (Regional hospital pharmacist 1)
The Public Finance Management Act (PFMA) no. 1 of
1999 stipulates that supplier accounts should be paid within
a 30 day period from the day of receipt of a valid invoice
[32]. Some participants stated non-payment of suppliers as a
contributing factor to medicine shortages in their hospitals.
They explained that suppliers who were not paid on time
did not deliver stock ordered to hospitals. As a result, the
availability of requested medicines was affected.
Theme 3: integrated computerized inventory
management system (RxSolution)
In 2014, the Gauteng Province implemented an elec-
tronic pharmaceutical management system, referred to
as RxSolution, to manage the inventory in the public
sector healthcare institutions. Four of the ten partici-
pants raised specific concerns with RxSolution. They
complained that the pharmacy staff did not use the soft-
ware appropriately making inventory management a dif-
ficult task. Stock was not received and issued correctly,
and the consumption data produced by RxSolution was
not reliable. This made it difficult to quantify orders.
Quantities ordered based on these unreliable consump-
tion data by some hospitals subsequently led to medicine
shortages because insufficient quantities that were ordered
did not meet the needs of their patients. In some hospitals,
staff also lacked confidence in the use of RxSolution. As a
result, its use was minimal. Counting and verifying stock
physically was also undertaken by storeroom staff due to
the fact that the quantities produced by the software were
not always reliable. However, one participant expressed a
view that the use of the RxSolution system in their
hospital helped with stock management. Information on
soon to expire medicines was retrieved from the software.
The short-dated stock report generated by the RxSolution
system helped the hospital to redistribute stock to other
hospitals that were in need of the stock and they were able
to utilise these medicines before they expired. This helped
in minimising waste in this hospital and improving medi-
cines availability in other hospitals.
“Yes, it (RxSolution) actually runs a report, and can
tell you which items are expiring and when. That re-
port helps us to know the short dated stock so that
we can start redistributing it to other hospitals as
well” (Regional hospital pharmacist 4)
However, overall it became evident there were con-
cerns generally with RxSolution.
“We still need to work on the accuracy of the system. I
am still not confident about it. The stock levels on the
system are not the same as the stock levels on the
shelves. We cannot rely on what is on the system
therefore we always have to verify the quantities phys-
ically on the shelves.” (Tertiary hospital pharmacist 2).
There were also concerns about updating the RxSolu-
tion system when issuing and receiving stock, and did
not even keep physical records.
“You think you’ve got stock because the bin card
and the computer are telling you that, but actually
there would be nothing on the shelves. People take
stock and they don’t update the system and don not
even record in the book, so the data on the system is
inaccurate then it affects our ordering.” (Central
hospital pharmacist 2).
Discussion
While the causes of medicines shortages are well known,
we believe this is the first comprehensive study to ex-
plore pharmacists’ experiences with medicines shortages
in South Africa. Our results have shown that the chal-
lenges experienced with medicines shortages did not dis-
criminate against the different categories of the hospitals
as they were similar across all levels of care. The main
findings highlighted the challenges in the procurement
process which included the non-payment of suppliers,
poor supplier performance, a lengthy buy-out process,
and a shortage of APIs. Our study also highlighted the
challenges with the use of the integrated computerised
inventory management system (RxSolution) used to
manage pharmaceutical inventory in the hospitals: how-
ever this was not universal.
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Whilst the PFMA no. 1 of 1999 in South Africa stipu-
lates that suppliers should be paid within the 30 day
period from receipt of a valid invoice, pharmacists re-
ported that suppliers were not always paid on time and
as a result, they did not supply the hospitals with their
orders. Subsequently, hospitals waited for longer periods
of time for their orders to be delivered. To compound
the situation, as mentioned, suppliers did not typically
inform hospitals in advance about possible medicine
shortages due to accounts that were outstanding, with
hospitals only getting to know about the problem of out-
standing accounts when they follow-up on outstanding
orders with the suppliers. These findings are similar to
those of Muhia et al. in Kenya where the non-payment
or late payment of suppliers was one of the key factors
that affected the procurement of medicines [23]. The
NDoH in South Africa in an attempt to prevent non-
payment of supplier accounts posed penalties to Prov-
inces that were found guilty of such conduct [15]. We
will investigate this further in future studies to help
reduce medicine shortages and their consequences. For
instance, the Organization of Eastern Caribbean States
(OECS) Pharmaceutical Procurement Service (PPS) was
established in 1986 to manage the procurement process
of member countries of the OECS to help address such
issues. OECS/PPS procures pharmaceuticals on behalf of
nine different countries through a tender process and
deals with problems such as slow payments of supplier
accounts. Hence, the OECS/PPS can provide guidance
to countries, including South Africa, experiencing drug
shortages due to non-payments by individual hospitals
to suppliers [24]. In 2010, a task team appointed by the
NDoH considered the challenges and opportunities for
improvement of medicines procurement in South Africa’s
public sector. One of its recommendations was the estab-
lishment of the Central Pharmaceutical Procurement
Agency (CPPA). This agency would manage procurement
contracts on behalf of the provinces, and provide oversight
to the payment of suppliers of pharmaceutical and
pharmaceutically related goods and services. The imple-
mentation of this recommendation by the NDoH could be
a solution to non-payment of suppliers, thus reducing
problems of out of stock medicines [29]. At the Provincial
level, fully functional Medicine Procurement Units
(MPUs) are a potential solution as they are responsible for
contract management at the operational level, therefore
increasing access and availability of medicines at lower
costs [19, 22]. This development will be monitored in
future studies.
As mentioned, participants reported that their hospi-
tals waited for long periods of time before their orders
were delivered, and in some instances, suppliers deliv-
ered quantities less than the order. In addition, pharma-
cists reported being given incorrect information about
stock availability leading to medicine shortages similar
to previous findings in South Africa [25]. This is also
similar to findings in Zimbabwe, where delayed deliv-
eries and non-deliveries of pharmaceuticals by sup-
pliers resulted in situations of medicine shortages
[42]. The late delivery of pharmaceuticals was also
one of the key findings in the Auditor General′s re-
port (2016), further confirming the findings of our
study. Penalties were not imposed by some medical
depots on suppliers for late delivery of pharmaceuti-
cals, which needs to be followed up [19].
The management of supplier contracts after the tender
award is crucial in ensuring supplier compliance and im-
proving medicine availability. The strategy of proper
contract management used by the Kenya Medical
Supplies Authority (KEMSA) could be the solution to
the problem of non-performance of suppliers in Gauteng
[14]. The MPUs are an important feature of the re-
formed supply chains in South Africa and a full imple-
mentation of MPUs may help validate the orders from
facilities, make follow up on orders easier, collate
documents to create payment packs, manage supplier
performance as well as facilitate facility and supplier
interaction [22].
Buy-outs result from the factors such as non-
performance of suppliers and certain essential medicines
not on tender. The pharmacists reported being frus-
trated by the buy-out process as this process can be very
long, involving considerable paper work and taking up
considerable time that could be profitably spent else-
where. As a result, the current long and complex nature
of this process caused medicine shortages in the hospi-
tals and patient care was compromised, similar to previ-
ous findings [29]. The NDoH should make it its goal to
safeguard contract management and to improve medi-
cines availability in public sector hospitals. Tenders
awarded on time may reduce the number of buy-outs,
ease the burden that comes with doing buy-outs at the
institutional level and improve medicine availability.
These are considerations for the future.
Shortage of APIs affects many manufacturers world-
wide, causing medicine shortages and leading to con-
cerns with patient management [5, 43, 44]. Shortage of
APIs was cited by the pharmacists as a reason given by
suppliers when they were unable to supply orders of cer-
tain medicines. The participating pharmacists under-
stood that the shortage of APIs not only affected South
Africa but many other countries around the world. The
reason for this can be that there is a limited number of
raw material suppliers globally with China and India be-
ing the major producers of APIs [12]. In the study by
Heiskanen et al. [2], shortage of raw materials was a
common reason for shortage of medicines in agreement
with our findings. The shortage of medicines including a
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lack of APIs has been a challenge in many countries re-
quiring Governments to collaborate and to coordinate ef-
forts and to find global solutions [10]. In addition,
pharmacists and others should also agree in advance po-
tential alternatives that could be used to limit the impact.
In addition, at a summit in Accra in 2007, heads of
states and governments of the African Union endorsed
the Pharmaceutical Manufacturing Plan for Africa [45],
with expansion of API manufacturing as one of the
principal goals to improve access to affordable, safe and
efficacious essential medicines in line with WHO sug-
gestions for LMICs [46]. In 2017, South Africa planned
to open a pilot plant for production of APIs however to
date this has not materialised. Opening of this plant was
going to be, an important first step towards reducing the
potential for medicine shortages of essential medicines
[47]. The latest manufacturing technology should help
deal with technology barriers as African countries seek
to produce more advanced APIs in the future similar to
the situation in Brazil [48]. Another potential strategy to
help address shortages of APIs would be the establish-
ment of a global shortage notification system that would
enable countries to better manage such shortages [12].
This study highlighted the challenges of inventory
management with the use of the electronic inventory
management programme (RxSolution) among public
hospitals in South Africa. However, this was not helped
by RxSolution being used inappropriately with some staff
members not entering the stock that was received and
issued into the system. As a result, unreliable consump-
tion data were generated with subsequent order quan-
tities generated by the system potentially being not
enough and causing medicine shortages in these hospi-
tals. In addition, some of the pharmacists reported that
they were still not confident enough to use RxSolution,
which was a concern. ChePa et al. (2017) highlighted
there could be negative mind-sets and perceptions dur-
ing the implementation of the electronic inventory man-
agement systems in hospitals making change hard to
implement [49]. Consequently, effective change manage-
ment strategies are crucial in the future to ensure a
smooth transition to new technologies [49]. However,
whilst the implementation of RxSolution in some hospi-
tals in this study did not produce the desired results, its
implementation at the Intermediate Hospital Oshikata in
Namibia yielded positive results [50]. With improved ac-
curacy of the stock cards, rational ordering of medicines
and a reduction in emergency orders. As a result, pro-
viding direction for the future to help reduce medicine
shortages among public sector hospitals in South Africa.
Overall based on our findings, we believe improved ef-
forts should be made by the (NDoH) to manage supplier
contracts during the pre-award and post-award process
to avoid awarding tenders to companies that do not
qualify to be suppliers. This builds on current initiatives
to improve the supply chain and obtain low prices for
medicines through tenders [22, 51]. The NDoH should
make it a point that tenders are awarded for all medi-
cines on the EML to minimise buy-outs. We also believe
the NDoH should re-look at the buy-out processes and
potentially remove this burden from hospitals through
national discussions in order for hospital pharmacists to
concentrate on other areas to improve patient care.
Change management programmes should also be pro-
duced in advance to help ensure a smooth transition
when Information Systems are being implemented, such
as RxSolution, given the concerns identified. The culture
of any hospital institution should be thoroughly under-
stood before any change can be introduced to mitigate
against resistance. In addition, there should be ongoing
monitoring and support in the hospitals to make sure
that the use of new systems such as RxSolution is maxi-
mised to help reduce medicine shortages in the future.
Purposive sampling was used in this study and there-
fore we acknowledge possible selection bias. This was
however minimised by selecting participants based on
the number of years’ of experience in managerial posi-
tions, to ensure that information rich participants were
recruited. Interviewer bias was minimized through inter-
viewer training prior to the first interview. Audio-
recording of interviews further minimized interviewer
bias, as it was not necessary for the interviewer to manu-
ally transcribe the responses during the interview. Fur-
thermore, all data were re-coded by the second author,
followed by review of codes and discussion between the
two coders until agreement on the coding was reached.
We are aware of a number of limitations of this study.
The sample size of pharmacy managers used as partici-
pants in the study was small and limited only to one of
the nine provinces in South Africa. Because of the quali-
tative nature of this study, which involved a small sam-
ple size the aim is not to formulate a generalized
hypothesis, but to extract the essence of the experience
[40]. Consequently the findings of the study may not be
generalized to all public sector hospitals in South Africa.
Although the drug controllers, who often deal with lo-
gistics management, were part of the hospitals that took
part in the study, they were not available for interviews.
Consequently, we missed an opportunity of getting a
perspective different from that of the pharmacy man-
agers on the shortage of medicines. However despite
these limitations, we believe our findings are robust and
we would expect to see similar findings in other Prov-
inces in South Africa.
Conclusion
This study shows that the medicine shortages are still a
reality that affect different levels of hospitals in South
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Africa. The determinants of medicines shortages in-
cluded delayed payments to suppliers, non-performance
of suppliers, and shortages of APIs. There were also con-
cerns that RxSolution is not being used and understood
in the majority of hospitals. Its limited use can cause
medicine shortages in some instances. Ongoing monitor-
ing and support for pharmacy staff is necessary for
RxSolution to be used for proper and effective inventory
management in the hospitals, and to improve medicines
availability. There are ongoing programmes to address a
number of these concerns.
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